Calcium levofolinate

Phase 3Small molecule

FFujian Cancer Hospital

Calcium levofolinate is one of 95 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

First-Line TreatmentUnknown status

Colorectal CancerPhase 3

Active, not recruiting

First-Line TreatmentPreclinical

Unknown status

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

34 2

Keytruda

Merck & Co.

Phase 3

25 3

Opdivo

Bristol-Myers Squibb

Phase 3

24 4

Fudr

Pfizer

Phase 3

16 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 7

Botensilimab

AAgenus Inc.

Phase 3

10 8

5-Fu

TToray Industries, Inc

Phase 3

3 9

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 10

TQB2102

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Colorectal Cancer

NCT04776655

Q4 2028

Phase 3Recruiting

Biliary Tract Cancer

NCT07606599

Phase 3Recruiting

Biliary Tract Cancer

NCT07582315

Clinical

Trials by Indication[1]

Biliary Tract Cancer2 trials

A Phase III Randomized Controlled Clinical Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07606599·398 enrolled

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07582315·538 enrolled

First-line Treatment1 trial

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·N/A·NCT03045770·150 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Completed·UUniversity Hospital, Grenoble·Phase 1·NCT05546853·43 enrolled

Colorectal Cancer1 trial

Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)

Active, not recruiting·AAzienda USL Reggio Emilia - IRCCS·Phase 3·NCT04776655·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Calcium levofolinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcium levofolinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcium levofolinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFujian Cancer Hospital

Calcium levofolinate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Biliary Tract Cancer2 trials

First-line Treatment1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News